INCY · 10-Q · 2026Q3 · Full report

Other Oncology Product Demand

INCYTE CORP · 2026-10-29 · Importance 22 · Surprise 24

Increased demand for NIKTIMVO, MONJUVI/MINJUVI and ZYNYZ primarily drove higher other hematology and oncology net sales in the third quarter and first nine months of 2026. The company attributed growth to continued strong uptake in the U.S. and these products’ entry into additional markets outside the U.S. Pricing changes did not materially affect the increase.

Key facts

• Increased demand for NIKTIMVO, MONJUVI/MINJUVI, and ZYNYZ primarily drove the increase in other hematology and oncology net sales for the three and nine months ended September 30, 2026 compared with the corresponding 2025 periods. source
• Increased demand for NIKTIMVO, MONJUVI/MINJUVI, and ZYNYZ reflected continued strong U.S. uptake and entry into new markets outside the U.S.; price changes were not material. source